X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
With this funding, the company will test the new technology in lung cancer patients, capturing metastatic cancer cell clusters (MCCCs) in their blood.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Recipient: TumorGen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 26, 2021
Details:
First clinical Study to Combine ZEN-3694 with BMS’s immune checkpoint inhibitors nivolumab and ipilimumab for treatment of ovarian cancer.
Lead Product(s): ZEN-3694,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: ZEN-3694
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Zenith Epigenetics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 05, 2020
Details:
The grant will support the continued development of novel small molecules that inhibit the enzymatic activity of Quiescin Sulfhydryl Oxidase I (“QSOX1”) based on a lead compound. QSOX1 is a tumor-derived enzyme that is important for cancer growth, invasion and metastasis.
Lead Product(s): SPX-1009
Therapeutic Area: Oncology Product Name: SPX-1009
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Sapphire Biotech
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Funding August 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
